Hayden E. Klein

Third-line ponatinib is the optimal treatment option for patients with chronic myeloid leukemia in chronic phase (CML-CP) without T3151 mutation, said Elias Jabbour, MD, professor of medicine, Department of Leukemia, MD Anderson Cancer Center.

About 10% of patients with blood cancer, especially those with B-cell lymphomas, who did not make anti-spike antibodies after vaccination experienced breakthrough COVID-19 infection, said Lee Greenberger, PhD, chief scientific officer, Leukemia and Lymphoma Society.

Federico Stella, MD, University of Milan, explains why it was important to challenge the idea that the low-microbial protective diet is more beneficial than a nonrestrictive diet in patients with neutropenia.

Building equitable clinical trials means being thoughtful about trial design and criteria, said Matthew J. Maurer, DSc, statistician at Mayo Clinic, director of the statistics and informatics core of the Lymphoma Epidemiology of Outcomes (LEO) cohort.

The field of hemophilia therapy is advancing, with hemostatic rebalancing agents and gene therapy expected over the next year, said Steven W. Pipe, MD, a professor of pediatrics and pathology at the University of Michigan, Ann Arbor and medical director of the Pediatric Hemophilia and Coagulation Disorders Program and medical director of the Special Coagulation Laboratory.

Tom Robinson, vice president of global access at JDRF, lists 3 pieces of advice for groups looking to create indexes for other conditions similar to the Type 1 Diabetes (T1D) Index.

Due to the study’s small sample, further research is needed to understand the role of bromocriptine in reducing blood pressure and artery stiffness in youth with type 1 diabetes (T1D).

Emma Searle, PhD, consultant hematologist, The Christie Hospital NHS Foundation Trust, touches on key points learnt from MajesTEC-2 data and other data to look forward to at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition.

Neil Iyengar, MD, from Memorial Sloan Kettering Cancer Center, is expecting updates on therapies to fight human epidermal growth factor 2 (HER2)–positive breast cancer and novel antibody drug conjugates at the upcoming San Antonio Breast Cancer Symposium (SABCS).

The first priority isn't limiting the rise in type 1 diabetes (T1D) prevalence, it's limiting the rise of missing prevalence, said Tom Robinson, vice president of global access at JDRF.

A review including nearly 40 million total participants showed a statistically significant positive association between infection with COVID-19 and risk of type 1 or type 2 diabetes.

About 1 in 5000 males are born with hemophilia, according to Steven W. Pipe, MD, a professor of pediatrics and pathology at the University of Michigan, Ann Arbor and medical director of the Pediatric Hemophilia and Coagulation Disorders Program.

A more-developed version of the assay used in this study may help manage patients with acute decompensation of liver cirrhosis or acute-on-chronic liver failure before liver transplantation.

Jana K. Dickter, MD, associate clinical professor, Division of Infectious Diseases, City of Hope, addresses what health systems need to do to improve HIV therapy accessibility and affordability.

Now that long-acting injectables are approved, the next big concern is patient access, said Kevin N. Astle, PharmD, BCPS, BCACP, AAHIVP, CDES, assistant professor at the University of South Florida Taneja College of Pharmacy.

According to the study authors, bictegravir, emtricitabine, and tenofovir alafenamide (BIC/FTC/TAF) may be an option for simplification following viral suppression.

Nancy Reau, MD, section chief of hepatology at Rush University Medical Center, elaborates on how to improve provider knowledge on liver disease guidelines.

Updating the Type 1 Diabetes (T1D) Index each year with the latest data and literature and implementing feedback is important for at least the first few years, said Tom Robinson, vice president of global access at JDRF.

Serum bicarbonate level also did not appear to affect the accuracy of real-time continuous glucose monitoring (rtCGM) in pediatric diabetic ketoacidosis (DKA).

Tam C. Phan, PharmD, AAHIVP, assistant professor of clinical pharmacy, USC School of Pharmacy, talks about how HIV pre-exposure prophylaxis (PrEP) therapies in the pipeline address disparities in patient access and adherence.

Patients with Medicare Advantage (MA) were 1.5 times more likely to die within a month of surgical removal of their stomach or liver, and twice as likely to die within a month of oncologic surgery of the pancreas, compared with patients with traditional Medicare.

As patients come into clinic and receive appropriate follow-up, we can hopefully find ways to mitigate the increase in alcoholic hepatitis, said Nancy Reau, MD, section chief of hepatology at Rush University Medical Center.

Get type 1 diabetes (T1D) communities involved in solving the problem and implementing T1D interventions in your country, said Tom Robinson, vice president of global access at JDRF.

A combination of possible factors could be contributing to a recent uptick in hospitalizations for alcoholic cirrhosis of the liver, said Nancy Reau, MD, section chief of hepatology at Rush University Medical Center.

The 10-year follow-up in the DIACAM 1 study demonstrated a notable increase in prevalence of different types of autoimmune diseases among patients with type 1 diabetes (T1D).

While each country has a different priority when it comes to type 1 diabetes (T1D) diagnosis and treatment, there is a fairly consistent outcomes checklist across nations, said Tom Robinson, vice president of global access at JDRF.

Jana K. Dickter, MD, associate clinical professor, Division of Infectious Diseases, City of Hope, discusses a patient's experience being the oldest person to successfully undergo a stem cell transplant while living with HIV and leukemia.

The disease groups that make up the OneOncology clinical pathways program cover 90% of patients with cancer and develop best practices for treating cancer in the majority of patients, said Edward “Ted” Arrowsmith, MD, MPH, managing partner and director of research, East Tennessee Division, Tennessee Oncology.

The OneOncology Annual Conference is being held November 11-13 in Nashville, Tennessee, and brings together practice leaders, physicians, and advanced practice providers to discuss the business of oncology and scientific advancements, explained Davey Daniel, MD, chief medical officer of OneOncology.

For the US health care system to be appropriately patient-centered, clinical trials need to be reflective of the country's diversity, said Joseph Alvarnas, MD, vice president of government affairs and senior medical director for employer strategy at City of Hope.